Comparison
Why is Citi Pharma Ltd. ?
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.63
2
Healthy long term growth as Net Sales has grown by an annual rate of 280.07% and Operating profit at 191.98%
3
Flat results in Mar 25
- OPERATING CASH FLOW(Y) Lowest at PKR -913.66 MM
- INTEREST(Q) At PKR 99.06 MM has Grown at 45.96%
- DEBT-EQUITY RATIO (HY) Highest at 29.09 %
4
With ROE of 14.9, it has a attractive valuation with a 3.5 Price to Book Value
- Over the past year, while the stock has generated a return of 0%, its profits have risen by 3.1% ; the PEG ratio of the company is 7.7
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Citi Pharma Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Citi Pharma Ltd.
192.37%
3.85
56.83%
Pakistan KSE 100 Share
60.28%
2.81
22.77%
Quality key factors
Factor
Value
Sales Growth (5y)
59.49%
EBIT Growth (5y)
78.07%
EBIT to Interest (avg)
8.63
Debt to EBITDA (avg)
0.27
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
1.62
Tax Ratio
30.09%
Dividend Payout Ratio
89.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.56%
ROE (avg)
13.90%
Valuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.95
EV to EBIT
14.04
EV to EBITDA
12.71
EV to Capital Employed
1.85
EV to Sales
1.71
PEG Ratio
3.39
Dividend Yield
NA
ROCE (Latest)
13.19%
ROE (Latest)
8.21%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
Technical Movement
2What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -11.27% (YoY
OPERATING PROFIT MARGIN(Q)
Highest at 13.53 %
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at PKR -913.66 MM
INTEREST(Q)
At PKR 99.06 MM has Grown at 45.96%
DEBT-EQUITY RATIO
(HY)
Highest at 29.09 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 3.34%
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.84%
Here's what is working for Citi Pharma Ltd.
Operating Profit Margin
Highest at 13.53 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Raw Material Cost
Fallen by -11.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at PKR 56.62 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (PKR MM)
Depreciation
At PKR 56.62 MM has Grown at 162.52%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (PKR MM)
Here's what is not working for Citi Pharma Ltd.
Interest
At PKR 99.06 MM has Grown at 45.96%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (PKR MM)
Operating Cash Flow
Lowest at PKR -913.66 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (PKR MM)
Debt-Equity Ratio
Highest at 29.09 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 3.34%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 4.84%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio






